Eisenmenger Syndrome: Closing the Hole (RCD code: IV-2B.1)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2014, Vol 1, Issue 6
Abstract
Eisenmenger syndrome represents the extreme manifestation of pulmonary arterial hypertension associated with congenital heart defects (CHD). Adults with CHD represent an increasing population which will require management in the long term. We present a case of a 38 year old female who presented with progressive dyspnea along with cyanosis at rest. Echocardiography showed a dilated right ventricle and an ostium secundum ASD with bidirectional shunting. Catheterization revealed severe pulmonary hypertension and evidence of partial anomalous pulmonary venous return. Warden procedure for PAPVR repair was performed along with a fenestrated pericardial ASD patch to close the shunt. A Maze Cox III procedure was also performed to treat the atrial fibrillation. Both procedures were performed successfully with significant improvement in patient’s clinical status. This article provides details regarding etiology, pathogenesis, clinical features, and diagnostic evaluation of Eisenmenger syndrome. It covers recent guidelines for screening and therapy as well as information regarding innovations in social and healthcare. JRCD 2014; 1 (6): 33–35
Authors and Affiliations
Hetain Patel, Pradip Jamnadas
Carotid body paragangliomas – clinical variety and management
Paragangliomas (PGLs) are a group of rare, slow‐growing tumours which are found between the base of the skull and the pelvis. The tumour is often asymptomatic, although a lump on the neck, cranial nerve palsy, or neck pa...
Third Conference of the Pulmonary Circulation Task Force of the Polish Cardiac Society
Third Conference of the Pulmonary Circulation Task Force of the Polish Cardiac Society was held on 8th‑9th November 2013 in Golebiewski Hotel in Bialystok. The Scientific Committee of the Conference constituted Prof. Mar...
Left ventricular non‐compaction – diagnostic challenges
Left ventricular non‐compaction (LVNC), or “spongy myocardium”, is a rare cardiac morphological condition detected in 0.05–0.26% of all adults undergoing transthoracic echocardiography, with an increasing prevalence in t...
Biventricular cardiomyopathy improvement by shifting therapy from agalsidase alfa to agalsidase beta in Anderson‐Fabry Disease
Treatment of Fabry disease has improved since the introduction of enzyme replacement therapy (ERT). Two preparations of the recom‐ binant enzyme α‐galactosidase A are available: agalsidase alfa and agalsidase beta. We ai...
Heart in Fabry Disease
Fabry disease is one of the lysosomal storage disorders, that results from progressive multiorgan accumulation of glycoproteins. It is caused by mutations of the GLA gene, which encodes alpha-galactosidase A. The incide...